Ipca Laboratories DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.76×	0.75×	0.69×	0.62×	0.64×
	1.01×	1.01×	0.85×	0.87×	1.12×
	17.8%	16.2%	14.9%	12.5%	10.7%
	0.80×	0.80×	0.78×	0.78×	0.77×
	1.30×	1.30×	1.40×	1.44×	1.46×
	14.1%	12.8%	9.6%	7.6%	8.6%
	15.2%	15.2%	11.1%	9.0%	8.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,926.20

Ipca Laboratories Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,868 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.64	0.62	0.69	0.75	0.76
Interest Burden (Pretax/EBIT) ×	1.12	0.87	0.85	1.01	1.01
EBIT Margin %	10.65	12.51	14.86	16.18	17.80
Asset Turnover ×	0.77	0.78	0.78	0.80	0.80
Financial Leverage (Assets/Equity) ×	1.46	1.44	1.40	1.30	1.30
ROE (5-step product, year-end total equity) %	8.61	7.61	9.61	12.75	14.11
ROE (owners' profit / average owners' equity) %	8.32	8.99	11.11	15.20	15.20

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.